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Available online 9 September 2016Human immunodeﬁciency virus type 1 (HIV-1) has evolved a sophisticated strategy to conceal conserved epi-
topes of its envelope glycoproteins (Env) recognized by antibody-dependent cellular cytotoxicity (ADCC)-medi-
ating antibodies. These antibodies, which are present in the sera of most HIV-1-infected individuals,
preferentially recognize Env in its CD4-bound conformation. Accordingly, recent studies showed that small
CD4-mimetics (CD4mc) able to “push” Env into this conformation sensitize HIV-1-infected cells to ADCC medi-
ated by HIV+ sera. Here we test whether CD4mc also expose epitopes recognized by anti-cluster A monoclonal
antibodies such as A32, thought to be responsible for the majority of ADCC activity present in HIV+ sera and
linked to decreased HIV-1 transmission in the RV144 trial. We made the surprising observation that CD4mc
are unable to enhance recognition of HIV-1-infected cells by this family of antibodies in the absence of antibodies
such as 17b, which binds a highly conserved CD4-induced epitope overlapping the co-receptor binding site
(CoRBS). Our results indicate that CD4mc initially open the trimeric Env enough to allow the binding of CoRBS
antibodies but not anti-cluster A antibodies. CoRBS antibody binding further opens the trimeric Env, allowing
anti-cluster A antibody interaction and sensitization of infected cells to ADCC. Therefore, ADCC responses medi-
ated by cluster A antibodies in HIV-positive sera involve a sequential opening of the Env trimer on the surface of
HIV-1-infected cells. The understanding of the conformational changes required to expose these vulnerable Env
epitopes might be important in the design of new strategies aimed at ﬁghting HIV-1.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
HIV-1
Envelope glycoproteins
CD4
Non-neutralizing antibodies
ADCC
CD4-mimeticscrobiology, Infectiology and
A9, Canada.
Richard),
. This is an open access article under1. Introduction
Several lines of evidence support a role for antibody-dependent cel-
lular cytotoxicity (ADCC) in controlling human immunodeﬁciency virusthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
209J. Richard et al. / EBioMedicine 12 (2016) 208–218type 1 (HIV-1) infection and replication (Alpert et al., 2012; Banks et al.,
2002; Baum et al., 1996; Chung et al., 2011; Forthal et al., 1999; Mabuka
et al., 2012; Sun et al., 2011;Williams et al., 2015). Analysis of the corre-
lates of protection in the RV144 vaccine trial suggested that decreased
HIV-1 acquisition was linked to increased ADCC activity in protected
vaccinees (Haynes et al., 2012). Accordingly, potent ADCC-mediating
antibodies (Abs) targeting anti-cluster A epitopes were isolated from
some RV144 vaccinees (Bonsignori et al., 2012) and were shown to
preferentially recognize the HIV-1 envelope glycoproteins (Env) in
their CD4-bound conformation (Veillette et al., 2014b). The CD4-
bound Env conformation is also recognized by non-neutralizing CD4-in-
duced (CD4i) ADCC-mediating antibodies present in sera (Veillette et
al., 2015; Richard et al., 2015; Richard et al., 2016; Williams et al.,
2015), breast milk (Richard et al., 2015) and cervicovaginal lavages
(Batraville et al., 2014; Richard et al., 2015) of HIV-1-infected individ-
uals. These antibodies represent a signiﬁcant portion of the anti-Env
Abs elicited during natural HIV-1 infection (Veillette et al., 2015;
Decker et al., 2005). However, to limit the exposure of CD4-bound Env
on the surface of infected cells, HIV-1 evolved sophisticated mecha-
nisms to efﬁciently internalize Env (Von Bredow et al., 2015), to coun-
teract the host restriction factor BST-2 with the viral Vpu protein
(Arias et al., 2014; Alvarez et al., 2014; Veillette et al., 2014b), and to
downregulate CD4 by Nef and Vpu (Veillette et al., 2015; Veillette et
al., 2014b). The requirement to evade ADCC provides one explanation
why the vast majority of circulating HIV-1 strains worldwide express
functional Nef and Vpu proteins, which limit the exposure of CD4i Env
epitopes on the surface of infected cells.
In agreement with the requirement for HIV-1 to avoid exposing the
CD4-bound conformation of Env, we recently showed that forcing Env
to adopt this conformation with small CD4-mimetics (CD4mc) sensi-
tizes HIV-1-infected cells to ADCC mediated by non-neutralizing Abs
present in sera, breast-milk and cervicovaginal ﬂuids fromHIV-1-infect-
ed subjects (Richard et al., 2015). These non-neutralizing ADCC-mediat-
ing Abs target gp120 epitopes that overlap the epitope recognized by
the anti-cluster A A32 Ab (Ferrari et al., 2011; Guan et al., 2013;
Veillette et al., 2015; Veillette et al., 2014b; Ding et al., 2016). But
whether these anti-cluster A Abs respond to CD4mc is not yet known.
Here we tested whether CD4mc expose epitopes recognized by anti-
cluster A Abs and enhance the susceptibility of HIV-1-infected cells to
ADCC mediated by this class of antibodies.
2. Materials and Methods
2.1. Cell Lines and Isolation of Primary Cells
293T human embryonic kidney cells (obtained from ATCC, Cat#
CRL-3216, RRID:CVCL_0063), CEM.NKr cells (obtained from Dr. David
Evans, Harvard Medical School) and primary cells were grown as previ-
ously described (Richard et al., 2010; Veillette et al., 2014b). CD4 T lym-
phocytes were puriﬁed from resting PBMCs by negative selection and
activated as previously described (Richard et al., 2015).
2.2. Viral Production, Infections, Ex Vivo Ampliﬁcation and Detection of In-
fected Cells
Vesicular stomatitis viruses G (VSVG)-pseudotyped viruses were
produced and titrated as described (Veillette et al., 2015). Viruses
were used to infect CEM.NKr cells or primary CD4 T cells from
healthy donors by spin infection at 800 g for 1 h in 96-well plates
at 25 °C. In order to expand endogenously-infected CD4 T cells,
primary CD4 T cells were isolated from PBMCs obtained from viremic
HIV-1-infected individuals. Puriﬁed CD4+ T cells were activated
with PHA-L at 10 μg/ml for 36 h and then cultured for 7 days in
RPMI-1640 complete medium supplemented with rIL-2 (100 U/ml)
(obtained from the NIH AIDS Reagent Program, Cat# 136).2.3. CD4-mimetics
The mini-protein M48U1 was produced and puriﬁed as previously
described (Martin et al., 2003). The CD4-mimetic small molecules JP-
III-48 and BNM-III-170 were synthesized as described (Melillo et al.,
2016). The compounds were dissolved in dimethyl sulfoxide (DMSO)
at a stock concentration of 10 mM, aliquoted, and stored at −20 °C.
Each compound was then diluted to 50–100 μM in PBS for cell-surface
staining or in RPMI-1640 complete medium for ADCC assays.
2.4. Antibodies and Sera
The anti-cluster A mAbs A32, C11 and N5-i5 were conjugated with
Alexa-Flour 647 probe (Thermo Fisher Scientiﬁc, Cat# A20186) as per
the manufacturer instructions and used for cell-surface staining of
HIV-1-infected primary CD4+ T cells at 0.35 μg/ml. The following
anti-EnvmAbswere used in combination of anti-cluster AmAbs during
cell-surface staining: 48d, 412d, 19b (kindly provided by Dr. J. Robin-
son), VRC01, b12 (NIH AIDS Reagent, Cat# 12033 and 2640), CH58
(kindly provided by Dr. B. Haynes), C2 and the Fab fragments, Fab′2
fragments or full 17b and N12-i2 mAbs. Goat anti-human Alexa Fluor-
647 mAbs (Thermo Fisher Scientiﬁc, Cat# A-21445 RRID:AB_2535862)
were used as secondary Abs for sera binding and AquaVivid (Thermo
Fisher Scientiﬁc, Cat# L43957) as a viability dye.
Sera from HIV-infected (Supplemental Table 1) and healthy donors
were collected, heat-inactivated and conserved as previously described.
Written informed consent was obtained from all study participants [the
Montreal Primary HIV Infection Cohort (Fontaine et al., 2011; Fontaine
et al., 2009) and the Canadian Cohort of HIV Infected Slow Progressors
(Peretz et al., 2007; Kamya et al., 2011; International et al., 2010)], and
research adhered to the ethical guidelines of CRCHUM and was
reviewed and approved by the CRCHUM institutional review board
(ethics committee). Research adhered to the standards indicated by
the Declaration of Helsinki. All sera were heat-inactivated for 30 min
at 56 °C and stored at 4 °C until ready to use in subsequent experiments.
A random number generator (GraphPad, QuickCalcs) was used to ran-
domly select a number of sera for each experiment.
2.5. Plasmids
pNL43-ADA(Env)-GFP.IRES.Nef proviral vector was previously de-
scribed (Veillette et al., 2015). The plasmid encoding the HIV-1 trans-
mitted founder (T/F) IMC CH58 was previously described
(Ochsenbauer et al., 2012; Bar et al., 2012; Parrish et al., 2013;
Fenton-May et al., 2013; Richard et al., 2015).
2.6. Flow Cytometry Analysis of Cell-surface Staining and ADCC Responses
Cell-surface stainingwas performed as previously described andMFI
histograms shows signal on live infected populations (Richard et al.,
2015; Veillette et al., 2015). Binding of HIV-1-infected cells by HIV+
sera (1:1000 dilution) or Alexa-Fluor 647-conjugated anti-cluster A
Abs A32, C11 and N5-i5 was performed 48 h after in vitro infection or
7 days post-activation for endogenously-infected (clade B) ex-vivo-am-
pliﬁed cells, in presence of CD4mc JP-III-48 (50 μM), BNM-III-170
(50uM), M48U1 (100 nM) or with equivalent volume of vehicle
(DMSO). Binding of HIV-1-infected cells with Alexa-Fluor 647-conju-
gated anti-cluster A Abs A32, C11 and N5-i5 was performed alone or
in combination with different mAbs or Fab fragments (5 μg/ml), or in
combinationwithHIV- or HIV+ sera (1:1000 dilution), with or without
Fab fragments of 17b or N12-i2 (5 μg/ml). Detection of GFP+ or p24+
infected cells was performed as described (Richard et al., 2015). The
percentage of infected cells (GFP+ or p24+ cells) was determined by
gating the living cell population based on the viability dye staining
(Aqua Vivid, Thermo Fisher Scientiﬁc, Cat# L43957). Samples were an-
alyzed on a LSRII cytometer (BD Biosciences, Mississauga, ON, Canada)
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Ashland, OR, USA).
Measurement of ADCC-mediated killing was performed with a pre-
viously described assay (Richard et al., 2015). Brieﬂy, primary CD4+ T
cells infected for 48 h with the CH58 T/F virus were incubated with au-
tologous PBMC (Effector: Target ratio of 10:1) in presence of A32
(0.3125, 0,625, 1,25 or 2,5 μg/ml, kindly provided by Dr. G. Ferrari)
and 17b (5 μg/ml) or17b Fab fragments alone or in combination, or
with HIV+ sera (1:1000), in presence of CD4mc JP-III-48, BNM-III-170
or with equivalent volume of vehicle (DMSO). The percentage of cyto-
toxicity was calculated as described (Richard et al., 2015).
2.7. Statistical Analyses
Statistics were analyzed using GraphPad Prism version 6.01
(GraphPad, San Diego, CA,USA). Every data set was tested for statistical
normality and this information was used to apply the appropriate
(parametric or nonparametric) statistical test. P values b0.05 were con-
sidered signiﬁcant; signiﬁcance values are indicated as *p b 0.05,
**p b 0.01, ***p b 0.001, ****p b 0.0001.
3. Results
3.1. CD4mc Fail to Enhance Recognition of HIV-1-infected Cells by ADCC-
mediating Anti-cluster A Abs
We recently reported that small CD4mc enhance the recognition of
HIV-1-infected cells by autologous and heterologous sera in both in
vitro and ex vivo experiments (Richard et al., 2015; Lee et al., 2015). Ac-
cordingly, primary CD4+ T cells infectedwith a pNL4.3 full-length HIV-
1 molecular clone coding for the primary ADA Env and a GFP reporter
gene (NL4.3 ADA GFP) were better recognized by HIV+ sera after the
addition of rationally-designed small CD4mc compounds (JP-III-48,
BNM-III-170) (Melillo et al., 2016) or CD4-mimetic peptides (M48U1)
(Van Herrewege et al., 2008) (Fig. 1A). These molecules engage gp120
within the Phe43 cavity (Madani et al., 2008; Melillo et al., 2016) and
can act as CD4 agonists, inducing thermodynamic changes in the Env
trimer similar to those observed upon membrane CD4 binding (Schon
et al., 2006; Lalonde et al., 2012). As previously reported (Ding et al.,
2016; Richard et al., 2015; Veillette et al., 2015), Env present on the sur-
face of cells infectedwith a wild-type (wt) virus is poorly recognized by
HIV-1+ sera (Fig. 1A, C). This is due to efﬁcient CD4 downregulation by
the virus; Env cannot engagewith CD4 and therefore remains in the un-
bound conformation, preventing CD4i epitope exposure (Veillette et al.,
2015; Veillette et al., 2014a; Veillette et al., 2014b). However, CD4mc
promote the exposure of Env CD4i epitopes, resulting in enhanced rec-
ognition of Env on the surface of HIV-1-infected cells by HIV-1+ sera
known to contain high levels of CD4i antibodies (Fig. 1A, C) (Decker et
al., 2005; Veillette et al., 2015).
It has been previously shown that ADCC-mediating anti-cluster A
Abs such as A32 recognize a highly-conserved region in gp120 that is
buried inside the Env trimer on the surface of HIV-1-infected (p24+)
cells and is not readily accessible in the ligand-free closed state
(Veillette et al., 2014b; Ding et al., 2016; Acharya et al., 2014; Von
Bredow et al., 2016; Tolbert et al., 2016). This explains why the A32 an-
tibody recognizes HIV-1-infected cells poorly in the absence of CD4mc
(Fig. 1B, D), yet efﬁciently recognizes shed gp120 bound to CD4 on the
surface of CD4+ uninfected bystander cells present in cultures of HIV-
1-infected cells (Richard et al., 2016). We therefore explored the capac-
ity of different CD4mc to promote the CD4-bound conformation of Env
and thereby enhance Env recognition on the surface of HIV-1-infected
cells by the anti-cluster A class of antibodies. Surprisingly, none of the
CD4mc tested (JP-III-48, BNM-III-170, M48U1) were able to enhance
recognition of wild-type HIV-1-infected cells by anti-Cluster A Abs
(A32, N5-i5, C11) (Fig. 1 B, D–F) at concentrations that were sufﬁcient
to enhance recognition by HIV+ sera (Fig. 1A, C). This is in contrastwith the effects ofmembrane-bound CD4,which has been shown to en-
able A32 recognition (Veillette et al., 2014b). Apparently, the conforma-
tional changes in Env induced by CD4mc differ qualitatively or
quantitatively from those induced by membrane-bound CD4.
3.2. CD4mc Enhance Recognition of HIV-1-infected Cells by Anti-cluster A
Abs in the Presence of HIV+ Sera
It was previously shown that the ADCC activity present in sera from
chronically HIV-1-infected individuals could be blocked by an A32 Fab
fragment (Ferrari et al., 2011). Subsequent studies showed that the ma-
jority of ADCC responses were targeted against the conserved gp120
core but not the gp120 variable regions V1, V2, V3 and V5 (Veillette et
al., 2015). Some ADCC responses depended on the highly-conserved
tryptophan 69 (W69) of the gp120 inner domain, required for some
anti-cluster A antibody binding (Ding et al., 2016; Tolbert et al., 2016).
Therefore, if the ADCC activity present in HIV+ sera is mediated by
anti-cluster A Abs and CD4mc enhance this activity, why then do
CD4mc fail to augment recognition of Env by anti-cluster A antibodies?
We hypothesized that a different class of antibodies present in the sera
of HIV-1-infected individuals enabled anti-cluster A antibodies to recog-
nize Env in the presence of CD4mc. To test this possibility, we infected
primary CD4+ T cells with the NL4.3 ADA GFP virus and evaluated
the ability of HIV+ sera to enhance the recognition of these HIV-1-in-
fected cells by anti-cluster A antibodies upon CD4mcaddition.Monoclo-
nal A32 and N5-i5 antibodies recognize an epitope located at the
interface of the gp120 inner domain Layers 1 and 2 (Veillette et al.,
2014a; Finzi et al., 2010; Acharya et al., 2014; Tolbert et al., 2016),
whereas C11 recognizes the N- and C-termini of gp120 (Finzi et al.,
2010;Moore et al., 1994;Gohain et al., 2015). To unequivocallymeasure
the binding capacity of these antibodies to HIV-1-infected cells in the
presence of CD4mc, with and without co-incubation with HIV+ sera,
A32, N5-i5 and C11 were conjugated to the Alexa-Fluor 647 probe. Re-
markably, the addition of a 1/1000 dilution of sera from10HIV-1-infect-
ed individuals but not from healthy donors enhanced recognition of
infected cells by these antibodies in the presence of all three CD4mc
(Fig. 2 and Supplemental Fig. 1). Importantly, similar results were ob-
tained with the unmodiﬁed clinically-relevant primary transmitted/
founder (T/F) virus CH58 (CH58 T/F) and endogenously-infected ex-
vivo-ampliﬁed primary CD4+ T cells from HIV-1-infected individuals
(Fig. 3), indicating that the phenomenon is not restricted to laborato-
ry-adapted viruses. These results suggest that some antibodies present
in the sera of HIV-1-infected individuals facilitate the exposure of anti-
cluster A epitopes upon CD4mc addition.
3.3. CoRBS Abs Allow Recognition of HIV-1-infected Cells by Anti-cluster A
Abs
In the same report describing the ADCC blocking capacity of the A32
Fab (Ferrari et al., 2011), the Fab fragment from the 17b antibody,which
belongs to the co-receptor binding site (CoRBS) family of anti-Env anti-
bodies (Wyatt et al., 1995), was able to block the ADCC activity in ap-
proximately 60% of the HIV+ sera tested. In some cases, the blocking
effect was comparable to that obtained with the A32 Fab (Ferrari et
al., 2011). To explore the possibility that CoRBS antibodies present in
sera from HIV-1-infected individuals facilitate Env recognition by anti-
cluster A antibodies in the presence of CD4mc, we added the Fab frag-
ments of 17b or another CoRBS antibody, N12-i2 (Guan et al., 2013),
to 10HIV+ sera. In all the HIV+ sera tested, addition of CoRBS Fab frag-
ments decreased the recognition of cells infected with CH58 T/F viruses
(Fig. 3 A–B) and endogenously-infected ex-vivo-ampliﬁed primary
CD4+ T cells from three HIV-1-infected individuals (Fig. 3D) by
Alexa-Fluor 647-conjugated A32 Abs (A32-AF647). These observations
suggest that CoRBS antibodies facilitate the access of anti-cluster A anti-
bodies to trimeric Env in the presence of CD4mc.
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Fig. 1. CD4mc fail to enhance recognition of HIV-1-infected cells by anti-cluster A antibodies. Primary CD4+ T cells, which were either mock-infected or infected with NL4.3 GFP
expressing the primary R5 ADA Env (NL4.3 ADA GFP), were stained with sera from 10 HIV-1-infected individuals followed by an anti-human Alexa-Fluor 647 (AF647)-conjugated
secondary antibody (a, c) or with (b, d) AF647-conjugated anti-cluster A (b, d) A32, (e) N5-i5 or (f) C11, in the presence of CD4mc JP-III-48, BNM-III-170, M48U1 or DMSO (vehicle).
Shown are histograms depicting representative staining obtained with (a) HIV+ sera or (b) A32-AF647 and (c-f) the mean ﬂuorescence intensities (MFI) obtained from at least three
experiments. Error bars indicate mean ± SEM. Statistical signiﬁcance was tested using a Kruskal-Wallis with a Dunn's post-test (**p b 0.01, ***p b 0.001, ns: non-signiﬁcant).
211J. Richard et al. / EBioMedicine 12 (2016) 208–218To test this conclusion directly, we co-incubated primary CD4+ T
cells infected with NL4.3 ADA GFP or CH58 T/F viruses in the presence
or absence of CD4mc with the full 17b antibody and evaluated A32-
AF647 and C11-AF647 recognition of infected cells. Incubation withthe 17b antibody was sufﬁcient to allow recognition of HIV-1-infected
cells by these two anti-cluster A antibodies (Fig. 4 A–C). Importantly,
while this was recapitulated by the 17b Fab′2 fragment, the 17b Fab
fragment was unable to do so (Fig. 4D). This was reiterated with a
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212 J. Richard et al. / EBioMedicine 12 (2016) 208–218different CoRBS (N12-i2) antibody and Fab fragments (Supplemental
Fig. 2), indicating that the bivalent recognition of Env by CoRBS antibod-
ies may be required to facilitate anti-cluster A antibody binding in thepresence of CD4mc. Of note, similar to the CD4mc JP-III-48,
soluble CD4 (sCD4) alone was unable to facilitate A32 recognition of
CH58 T/F-infected primary CD4+ T cells (Supplemental Fig. 3A).
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213J. Richard et al. / EBioMedicine 12 (2016) 208–218Interestingly, the 17b CoRBS antibody allowed recognition of CH58 T/F-
infected primary CD4+ T cells by the A32 antibody in the presence of
JP-III-48, but not in the presence of sCD4 (Supplemental Fig. 3B). Thisis in agreement with our previous observations indicating that CD4mc
but not sCD4 sensitize primary CD4+ T cells infected with primary
HIV-1 viruses to ADCC (Richard et al., 2015).
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evaluated the ability of well-established CoRBS antibodies (48d, 412d)
or a newly-isolated CoRBS antibody from a clade-B HIV-1-infected indi-
vidual (C2, Supplemental Fig. 4) to allow A32-AF647 or C11-AF647binding. All tested CoRBS antibodies facilitated A32-AF647 and C11-
AF647 binding upon CD4mc addition (Fig. 4 A–C). We also evaluated
whether this activity was shared by antibodies with different Env spec-
iﬁcities. We tested anti-V3 (19b), anti-V2 (CH58) and anti-CD4 binding
215J. Richard et al. / EBioMedicine 12 (2016) 208–218site (VRC01, b12) antibodies. These antibodies did not facilitate A32 rec-
ognition of infected cells in the presence of CD4mc (Fig. 4 A–B). These
observations suggest that antibodies that recognize CD4-induced epi-
topes near the CoRBS speciﬁcally enhance the recognition of the HIV-1
Env trimer by anti-cluster A antibodies in the presence of CD4mc. It re-
mains possible that antibodies with different Env speciﬁcities, present
in HIV+ sera, might also contribute to the exposure of epitopes recog-
nized by anti-cluster A antibodies.
3.4. CoRBS Abs Are Required for CD4mc to Sensitize Infected Cells to ADCC
Mediated by Anti-cluster A Abs
To evaluate whether the enhanced recognition of HIV-1-infected
cells by anti-cluster A antibodies in presence of CD4mc and CoRBS
mAbs resulted in ADCC killing, we infected primary CD4+ T cells with
CH58 T/F virus and evaluated their susceptibility to ADCC mediated by
autologous PBMCs using a previously-described FACS-based assaya
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Fig. 5. CD4-mimetic sensitize HIV-1-infected cells to ADCC-mediated by anti-cluster A
antibodies in the presence of CoRBS antibodies. Primary CD4 T cells infectedwith CH58
T/F were used as target cells and autologous PBMC as effector cells in our FACS-based
ADCC assay. Shown in (a) are the percentages of ADCC-mediated killing obtained with
serial dilution of A32 (0.3125, 0.625, and 1.25 μg/ml) alone or in combination with 17b
(5 μg/ml), in the presence of CD4mc JP-III-48 or equivalent volume of DMSO for 7
different experiments. Shown in (b) are the percentages of ADCC-mediated killing
obtained with A32 (0.3125 μg/ml), 17b, 17b Fab, alone or in combination, or with sera
from an HIV+ individual, in the presence of JP-III-48 or equivalent volume of DMSO.
Error bars indicate mean ± SEM. Statistical signiﬁcance was tested using an Ordinary
one-way ANOVA with a Holm-Sidak's post-test (***p b 0.001, ****p b 0.0001, ns: non-
signiﬁcant), See also Fig. S5 and S6.(Richard et al., 2014; Richard et al., 2015). As expected, A32 and 17b
alone or in combinationwere unable tomediate ADCC (Fig. 5). Recogni-
tion of HIV-1-infected cells by the CoRBS 17b antibody upon CD4mc ad-
dition (Supplemental Fig. 5) did not translate into enhanced ADCC
killing (Fig. 5). This is in agreement with recent reports indicating that
CoRBS antibodies do not mediate efﬁcient ADCC, despite good recogni-
tion of target cells when Env samples the CD4-bound conformation
(Ding et al., 2016; Guan et al., 2013). However, when the anti-cluster
A A32 and CoRBS 17b antibodies were added, at different concentra-
tions, in conjunction with CD4mc JP-III-48 or BNM-III-170, we observed
a marked increase in the killing of HIV-1-infected cells (Fig. 5 and Sup-
plemental Fig. 6), reminiscent of the CD4mc sensitization of infected
cells to ADCCmediated byHIV+ sera (Richard et al., 2015) (Fig. 5B). Im-
portantly, this response was only observed when the full 17b antibody
but not its Fab fragment was added in combination with A32 in the
presence of CD4mc (Fig. 5B). Thus, CD4mc and CoRBS antibodies partic-
ipate in the formation of a suitable target for ADCC responses mediated
by anti-cluster A antibodies.
4. Discussion
HIV-1 has evolved several mechanisms to avoid the robust humoral
response elicited against its envelope glycoproteins, including se-
quence-variable loops, extensive glycosylation, and conformational
masking of vulnerable epitopes (Kwong et al., 2002; Wyatt et al.,
1998; Wyatt and Sodroski, 1998). While the majority of the antibodies
elicited during natural infection are strain-speciﬁc neutralizing or non-
neutralizing antibodies (reviewed in Kwong and Mascola, 2012) and
thought to play only a minimal role in controlling viral replication, re-
cent studies showed that these antibodies can exert a constant selection
pressure through their weakly neutralizing activities and thus drive
viral evolution (Moody et al., 2015). In addition to their non- or weak-
ly-neutralizing activities, these antibodies possess Fc-mediated effector
functions with the potential to eliminate HIV-1-infected cells through
several immune responses, including ADCC. The analysis of the corre-
lates of protection in the RV144 vaccine trial suggesting that decreased
HIV-1 acquisition was linked to increased ADCC activity in protected
vaccinees (Haynes et al., 2012) spurred a renewed interest in these
Fc-mediated functions (Chung et al., 2015; Ackerman et al., 2016;
Williams et al., 2015; Veillette et al., 2014b; Ding et al., 2016; Richard
et al., 2015; Veillette et al., 2015; Richard et al., 2016; Ferrari et al.,
2011; Von Bredow et al., 2016). These ADCC-mediating antibodies ap-
pear to preferentially target Env in its CD4-bound conformation (Ding
et al., 2016; Veillette et al., 2015). In other words, these antibodies pri-
marily recognize Env epitopes exposed upon interaction with the viral
receptor CD4. To avoid exposing these epitopes at the surface of infected
cells, HIV-1 limits the amount of Env and CD4 present at the cell surface
(reviewed in Veillette et al., 2016).
Small CD4mcwith the capacity to “push” Env to the CD4-bound con-
formationwere recently shown to enhance the recognition of HIV-1-in-
fected cells by sera, cervicovaginal lavages and breast milk from HIV-1-
infected individuals (Richard et al., 2015). However, the speciﬁcity of
the antibodies mediating this response in these complex biological
ﬂuids was not known. Previous reports indicated that the ADCC activity
present in HIV+ sera is mediated by anti-cluster A antibodies (Guan et
al., 2013; Ferrari et al., 2011; Ding et al., 2016). Accordingly, competition
experiments using a gp120 inner domain recombinant protein exposing
only A32-like epitopes showed the importance of A32-like antibodies in
ADCC responses mediated by HIV+ sera (Tolbert et al., 2016). We
therefore evaluated whether CD4mc were able to sensitize HIV-1-in-
fected cells to ADCC by this family of antibodies. Surprisingly, all
CD4mc tested (M48U1, JP-III-48, BNM-III-170) failed to enhance recog-
nition of HIV-1 Env present on the surface of infected cells by anti-clus-
ter A antibodies. Interestingly, we found that HIV+ sera enabled
recognition of Env by anti-cluster A antibodies in the presence of
CD4mc. Importantly, this depended on the presence of CoRBS
gp41
gp120
CD4 mimetic
Cell membrane
anti-cluster A 
CoRBS
Fig. 6. Sequential opening of Env required for anti-cluster A antibodybinding. CD4mc induce a partial opening of trimeric Env allowing subsequent exposure of the co-receptor binding
site. Binding of Env by CoRBS antibodies induce additional conformational changes in Env resulting in the exposure of highly-conserved epitopes recognized by anti-cluster A antibodies.
Env exposing anti-cluster A epitopes become a suitable target for ADCC.
216 J. Richard et al. / EBioMedicine 12 (2016) 208–218antibodies. Indeed, 17b and N12-i2 Fab fragments were able to negate
the effect of HIV+ sera on Env recognition by these antibodies. More-
over, several CoRBS antibodies but not anti-V2, anti-V3 or anti-CD4bs
antibodies were able to recapitulate the effect of HIV+ plasma in the
presence of CD4mc; and the CoRBS antibodies facilitated ADCC-mediat-
ed killing of HIV-1-infected cells by the anti-cluster A family of antibod-
ies. Interestingly, the Fab′2 but not Fab fragments of CoRBS antibodies
were able to recapitulate the effect of full antibodies, indicating that
the bivalent recognition of Env by these antibodies is required to facili-
tate anti-cluster A antibody binding in the presence of CD4mc.
The unexpected requirement for CoRBS antibodies to allow Env rec-
ognition by anti-cluster A antibodies in the presence of CD4mc suggests
amodel for the sequential opening of trimeric Env. In thismodel (Fig. 6),
CD4mc engagement in the Phe43 cavity induces a partial opening of tri-
meric Env,which is sufﬁcient to expose the CoRBS but not enough to ex-
pose inner domain cluster-A epitopes. Interaction of CoRBS antibodies
with two gp120 subunits within this CD4mc-sensitized trimer further
opens the trimeric Env and exposes highly-conserved epitopes recog-
nized by anti-cluster A antibodies. It is unclear why a bivalent recogni-
tion of Env by CoRBS is required to expose anti-cluster A antibodies in
the presence of CD4mc. This could be related to a potential asymmetric
transition of Env upon CD4mc engagement towards downstream con-
formations, as suggested for CD4 binding (Personal communication,
Ma, Mothes, Munro). While in theory CD4mc should induce
conformational changes in all Envs with an available Phe 43 cavity
(the majority of HIV-1 strains), the results presented here have been
generated using clade B HIV-1 strains only. How these ﬁndings extend
to additional HIV-1 strains remains to be evaluated.
We previously reported that HIV-1 avoids exposing Env epitopes of
anti-cluster A antibodies through CD4 downregulation by Nef and Vpu
accessory proteins (Veillette et al., 2014b; Ding et al., 2016; Veillette et
al., 2015; Alsahaﬁ et al., 2016). Our ﬁndings herein indicate that several
conformational transitions are required to expose these epitopes and
suggest that trimeric HIV-1 Env has evolved tominimize their exposure.
This represents another example of conformational masking of vulner-
able epitopes and helps to explain why the A32 antibody failed to pro-
vide sterilizing protection in non-human primates (Santra et al.,
2015).Why has HIV-1 evolvedmultiple mechanisms to avoid anti-clus-
ter A epitope exposure? This highly-conserved region contributes to
Env stability (Finzi et al., 2010), so its buried nature may be critical for
preserving the global architecture of theHIV-1 Env trimer. This architec-
ture has evolved to minimize the exposure of this and other elements
that represent suitable targets for ADCC.
Altogether, our data highlights the difﬁculty of exposing anti-cluster
A epitopes at the surface of infected cells but also indicates that sera
from HIV-1-infected individuals have all the components required to
do so, provided that the initial opening of the trimer by CD4mc occurs.
While it is unknown at the moment whether CD4mc will ultimately
be used therapeutically to boost ADCC activity in vivo, the understand-
ing of the conformational changes required to expose anti-cluster Aepitopes might expedite the design and application of new strategies
aimed at ﬁghting HIV-1.
Supplementary data to this article can be found online at http://dx.
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